OptimizeRx Expands Natural Language Audience Builder for HCP and DTC Audiences

WALTHAM, Mass., Sept. 14, 2026 /CourierPR/ -- OptimizeRx Corp has expanded its Natural Language Audience Builder (NLAB) tool to unify the creation of healthcare professional (HCP) and direct-to-consumer (DTC) audiences in a single workflow. This enhancement allows media planners and buyers to build both claims-grade HCP audiences and privacy-safe DTC audiences from a shared plain-language prompt, transforming NLAB into a comprehensive platform for life sciences media planning.

The update integrates Micro-Neighborhood® Targeting (MNT) audiences into NLAB, enabling marketers to create and optimize both NPI lists and consumer segments in minutes. This streamlined process allows for seamless activation of these audiences across programmatic and other major media channels. According to Mike Rousselle, Chief AI Officer at OptimizeRx, the integration of MNT audiences into NLAB provides a more efficient way for marketers to build, refine, and activate consumer audiences, leading to higher marketing engagement and impact.

The expansion of NLAB also includes new optimization and media planning functionalities specific to the DTC landscape. These features include decile-based, interactive breakdowns of audience quality (AQ) and reach, allowing planners to adjust audience precision and scale in real-time to reflect different campaign goals. Additionally, instant generation of media channel propensities and audience demographics for NLAB-created audiences or natural language audience prompts enables the creation of media mix strategies optimized for specific brand populations.

By combining de-identified clinical and consumer data at the ZIP-9 level, MNT audiences offer hyperlocal precision and a scalable alternative to modeled or probabilistic targeting. This integration of MNT audiences into NLAB means that non-healthcare-native platforms or marketing agencies can now embed validated healthcare audience intelligence without investing in proprietary data or enterprise data licensing agreements.

Stephen Silvestro, CEO of OptimizeRx, emphasized the importance of this expansion.

This enhancement to NLAB is expected to reduce friction for DSPs, agencies, and their life sciences clients, making it easier to put sophisticated audience intelligence to work. As a result, OptimizeRx is positioning itself as a key player in the life sciences media planning landscape, offering a platform that can bridge the gap between HCP and DTC strategies to drive faster treatment decisions and improved patient outcomes.